MedCity News
DECEMBER 5, 2024
Many providers are still struggling to recover from the workforce crisis that emerged during the pandemic, two healthcare leaders said during a recent panel. The post Where Does Healthcares Workforce Crisis Stand? appeared first on MedCity News.
Fierce Pharma
DECEMBER 2, 2024
Robert F. Kennedy Jr.’s appointment last month to lead the U.S. Department of Health and Human Services immediately sent waves of speculation swirling throughout the biopharma industry. | The former FDA Commissioner pointed to the threat of measles if vaccination rates were to decline by 5%.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
DECEMBER 3, 2024
The MHRA has reminded pharma companies that from 1st January all medicines sold in the UK will have to comply with new labelling requirements
PharmaVoice
DECEMBER 4, 2024
Dr. Marty Makary’s conflicts of interest could come into question before he is confirmed as the next FDA commissioner.
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
MedCity News
DECEMBER 6, 2024
Leaders across healthcare, technology, and policy circles agree that cybersecurity isn’t just a technical necessity it’s foundational to patient safety The post Stronger Cybersecurity in Healthcare Starts with Smart Policy appeared first on MedCity News.
Fierce Pharma
DECEMBER 3, 2024
Over the last two-plus years, as Eli Lilly and Novo Nordisk have battled for their share of the massive weight loss market and patients wondered which company’s products were more effective, there | Eli Lilly revealed results from a study that showed its obesity drug Zepbound was 47% more effective than Novo’s Wegovy in helping patients lose weight.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
PharmaTimes
DECEMBER 5, 2024
New antibody therapy shows promise in managing condition
MedCity News
DECEMBER 4, 2024
Eli Lilly obesity drug Zepbound led to 47% greater relative weight loss compared to Wegovy in a head-to-head clinical trial. The results could help Lilly differentiate its product from Novo Nordisk’s in the increasingly competitive market of obesity medications. The post Eli Lilly’s Zepbound Leads to Greater Weight Loss vs. Novo Nordisk Drug in Head-to-Head Test appeared first on MedCity News.
Fierce Pharma
DECEMBER 4, 2024
AstraZeneca’s Daiichi Sankyo-partnered antibody-drug conjugate Enhertu has made it onto China’s national insurance program despite the star med being a part of an ongoing investigation in the count | AstraZeneca’s Daiichi Sankyo-partnered antibody-drug conjugate Enhertu has made it onto China’s national insurance program despite the star med being a part of an ongoing investigation in the country.
Pharmaceutical Technology
DECEMBER 1, 2024
The HIV vaccine space has seen dwindling research activity as drug manufacturers turn to PrEP therapies for preventive treatment.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
PharmaTimes
DECEMBER 4, 2024
Data highlights effectiveness of EVER001 in treating pMN
MedCity News
DECEMBER 5, 2024
The startup’s first disease target is chronic inflammatory demyelinating polyneuropathy (CIDP), which can be treated with a blockbuster Argenx drug. Nuvig aims to show its drug can offer a better way to treat this disease and other autoimmune conditions. The post Nuvig Therapeutics Nabs $161M to Build Case for a Better Approach to Autoimmune Disease appeared first on MedCity News.
Fierce Pharma
DECEMBER 5, 2024
AstraZeneca has picked off another label expansion for cancer blockbuster Imfinzi as the FDA has blessed it for limited-stage small cell lung cancer.
pharmaphorum
DECEMBER 4, 2024
The UKHSA has taken steps to prepare for a possible bird flu outbreak by placing an order with Seqirus for millions of H5 vaccine doses
PharmaTimes
DECEMBER 2, 2024
Race to create first oral drug for obesity intensifies
MedCity News
DECEMBER 3, 2024
When you combine clean data with longitudinal patient records and transparent access — that’s when you start seeing real transformation in care delivery. The post Set the Data Free: Break the Chains of Information Silos appeared first on MedCity News.
Fierce Pharma
DECEMBER 4, 2024
Merus’ week keeps getting better. | The FDA had originally pushed its decision back by three months after a November manufacturing-related delay.
Pharmaceutical Technology
DECEMBER 3, 2024
Olema Oncology and Novartis have signed a clinical trial collaboration and supply agreement for a Phase III trial in metastatic breast cancer.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
PharmaVoice
DECEMBER 6, 2024
MedCity News
DECEMBER 4, 2024
Fello’s $10.4 million raise includes a seed investment from Glen Tullman’s 62Ventures, The Capital Factory Fellowship Fund, Katalyst Capital and Offline Ventures. The post Peer Support Platform Fello Secures $10.4M To Combat Loneliness Epidemic appeared first on MedCity News.
Fierce Pharma
DECEMBER 2, 2024
The FDA is investigating reports of patients develo | The FDA is investigating reports of patients developing blood cancer after receiving bluebird bio’s gene therapy Skysona and is evaluating the need for “further regulatory action,” the U.S. agency said last week. The FDA notification came seven weeks after the New England Journal of Medicine (NEJM) published a report that seven of 67 children who received Skysona during clinical trials had developed blood cancer.
PharmaTimes
DECEMBER 5, 2024
Phase 3 trial indicates significant efficacy and safety for children and adolescents
Advertiser: ZoomInfo
Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr
pharmaphorum
DECEMBER 2, 2024
Novartis has made a return to the Huntington's disease stage by licensing an oral mRNA splicer from PTC Therapeutics for $1 billion upfront
MedCity News
DECEMBER 6, 2024
Dr. Maria Pulido, chief medical officer, of Ascension St. Vincents, explains why he believes tools like Wellsheet makes the hospital care team’s job so much easier. The post Why the CMO of an Ascension Regional Hospital Likes Wellsheet appeared first on MedCity News.
Fierce Pharma
DECEMBER 4, 2024
Amid a multi-year, multibillion-dollar spending spree to scale its global manufacturing capacity, Novo Nordisk is laying down fresh foundations at its old stomping grounds in Denmark to bolster a c | Novo will invest 2.9 billion Danish kroner (roughly $409 million) to construct a new, 53,000-square-meter quality control laboratory in Hillerød, Denmark.
PharmaVoice
DECEMBER 2, 2024
Intrinsic Medicines is entering phase 2 trials in Parkinson’s disease and IBS for its human milk oligosaccharide drug candidates next year.
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
pharmaphorum
DECEMBER 5, 2024
Many patients can expect a long wait for access to Eli Lilly's obesity shot Mounjaro, even though it has been recommended for routine NHS use by NICE
MedCity News
DECEMBER 4, 2024
The Glp-1 battle heats with new preliminary data from Eli Lilly showing that patients using its weight loss drug Zepbound lost more weight on average in 72 weeks than those on Novo Nordisk’s Wegovy. The post Video: Battle of the Bulge – Wegovy vs. Zepbound appeared first on MedCity News.
Fierce Pharma
DECEMBER 2, 2024
Shortly after a similarly sized venture from Pfizer, French pharma juggernaut Sanofi has unveiled a major manufacturing outlay in China, marking its biggest investment in the country to date. | Sanofi is laying out roughly 1 billion euros ($1.04 billion) to establish a new production base in the Beijing Economic and Technological Development Zone. The new manufacturing site, which will become Sanofi’s fourth in China, is being designed to beef up local end-to-end insulin production.
PharmaVoice
DECEMBER 4, 2024
Four companies that refreshed their mission and public persona with a new look.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Expert insights. Personalized for you.
105 
Let's personalize your content